While more research is needed, these findings open exciting new possibilities for brain health
the available evidence comes from clinical trial data rather than regulatory product information
Compounded alternatives are not a legal workaround
Vita Stir has been great to work with
Let our expert team help you unleash your body's fat-burning power
Its promise, according to Dr Levi Garraway, PhD, Roches Chief Medical Officer and Head of Global Product Development, results from the robust weight loss combined with a well-tolerated safety profile. Furthermore, at the end of last year, Pfizer paid a $2 billion for China-based manufacturer YaoPharmas GLP-1 drug, increasing competition in the expanding market, while in August Teva secured US approval for a generic GLP-1 of its version of Novo Nordisks injectable Saxenda (liraglutide).